Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Letrozole 9Fluorodeoxyglucose F18 7pembrolizumab 6Magnetic Resonance Spectroscopy 6atezolizumab 5Blood Specimen Collection 5Trastuzumab 4Oncolytic Virotherapy 4Biopsy 4Bevacizumab 4palbociclib 3durvalumab 3Vitamin D 3Taxes 3Saline Solution 3Radiotherapy 3Metformin 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Albumin-Bound Paclitaxel 3pertuzumab 2olaparib 2bazedoxifene 2Vinorelbine 2Tamoxifen 2Sentinel Lymph Node Biopsy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Introns × Breast × Clear all
NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡